High dose oral tamoxifen and subcutaneous interferon alpha-2a for recurrent glioma

Journal of Neuro-Oncology

Volumn 37, Issue 2, 1998, Pages 169-176

  Chang, Susan M ^a,b   Barker II, Fred G ^a   Huhn, Stephen L ^a   Nicholas, M Kelly ^a   Page, Margaretta ^a   Rabbitt, Jane ^a   Prados, Michael D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCSF Neuro Oncology   (United States)

Author keywords

Glioma; Interferon; Neurotoxicity; Phase II; Tamoxifen

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; NITROSOUREA; TAMOXIFEN;

ADULT; ARTICLE; ASTROCYTOMA; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; GLIOMA; HISTOLOGY; HUMAN; MALE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; OUTPATIENT CARE; PHASE 2 CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; VERTIGO;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BRAIN NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOMA; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME;

EID: 0031950726     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005826323652     Document Type: Article

References (49)

1. Liu G, Franssen E, Fitch MI, Warner E: Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 15: 110-115, 1997
2. Rodriguez LA, Prados M, Silver P, Levin VA: Reevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumors. Cancer 64: 2420-2423, 1989
3. O'Reilly SM, Newlands ES, Glaser MG, Brampton M, Rice-Edwards JM, Illingworth RD, Richards PG, Kennard C, Colquhoun IR, Lewis P, Stevens MFG: Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 29A: 940-942, 1993
4. Fulton D, Urtasun R, Forsyth P: Phase II study of prolonged oral therapy with etoposide (VP16) for patients with recurrent malignant glioma. J Neurooncol 27: 149-155, 1996
5. Baltuch G, Shenouda G, Langleben A, Villemure JG: High dose tamoxifen in the treatment of recurrent high grade glioma: a report of clinical stabilization and tumour regression. Can J Neurol Sci 20: 168-170, 1993
6. Could well WT, Weiss MH, DeGiorgio CM, Weiner LP, Hinton DR, Ehresmann GR, Conti PS, Apuzzo ML: Clinical and radiographic response in a minority of patients with recurrent malignant gliomas treated with high-dose tamoxifen. Neurosurgery 32: 485-490, 1993
7. Vertosick FT Jr., Selker RG, Pollack IF, Arena V: The treatment of intracranial malignant gliomas using orally administered tamoxifen therapy: preliminary results in a series of 'failed' patients. Neurosurgery 30: 897-903, 1992
8. Hirakawa K, Ueda S, Nakagawa Y, Suzuki K, Fukuma S, Kita M, Imanishi J, Kishida T: Effect of human leukocyte interferon on malignant brain tumors. Cancer 51: 1976-1981, 1983
9. Boëthius J, Blomgren H, Collins VP, Greitz T, Strander H: The effect of systemic human interferon-alpha administration to patients with glioblastoma multiforme. Acta Neurochir 68: 239-251, 1983
10. Mahaley MS Jr., Urso MB, Whaley RA, Blue M, Williams TE, Guaspari A, Selker RG: Immunobiology of primary intracranial tumors. Part 10: therapeutic efficacy of interferon in the treatment of recurrent gliomas. J Neurosurg 63: 719-725, 1985
11. O'Brien CA, Liskamp RM, Solomon DH, Weinstein IB: Inhibition of protein kinase C by tamoxifen. Cancer Res 45: 2462-2465, 1985
12. Horgan K, Cooke E, Hallett MB, Mansel RE: Inhibition of protein kinase C mediated signal transduction by tamoxifen. Importance for antitumour activity. Biochem Pharm 35: 4463-4465, 1986
13. Vertosick FT Jr., Selker RG, Randall MS, Kristofik MP, Rehn T: A comparison of the relative chemosensitivity of human gliomas to tamoxifen and n-desmethyltamoxifen in vitro. J Neurooncol 19: 97-103, 1994
14. Pollack IF, Randall MS, Kristofik MP, Kelly RH, Selker RG, Vertosick FT Jr.: Response of malignant glioma cell lines to activation and inhibition of protein kinase C-mediated pathways. J Neurosurg 73: 98-105, 1990
15. Couldwell WT, Uhm JH, Antel JP, Yong VW: Enhanced protein kinase C activity correlates with the growth rate of malignant glioma in vitro. Neurosurgery 29: 880-887, 1991
16. Couldwell WT, Hinton DR, He S, Chen TC, Sebat I, Weiss MH, Law RE: Protein kinase C inhibitors induce apoptosis in human malignant glioma cell lines. FEBS Lett 345:43-46, 1994
17. Couldwell WT, Antel JP, Yong VW: Protein kinase C activity correlates with the growth rate of malignant gliomas: part II. Effects of glioma mitogens and modulators of protein kinase C. Neurosurgery 31: 717-724, 1992
18. Pollack IF, Kawecki S: The efficacy of tamoxifen as an antiproliferative agent in vitro for benign and malignant pediatric glial tumors. Pediatr Neurosurg 22: 281-288, 1995
19. Lien EA, Wester K, Lonning PE, Solheim E, Ueland PM: Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br J Cancer 63: 641-645, 1991
20. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL: High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 84: 1811-1816, 1992
21. Stratton MR, Martin JM, Lantos PL: The effects of interferon on glial cells. Br J Exp Path 68: 643-653, 1987
22. Reddy PG, Graham GM, Datta S, Guarini L, Moulton TA, Jiang H, Gottesman MM, Ferrone S, Fisher PB: Effect of recombinant fibroblast interferon and recombinant immune interferon on growth and the antigenic phenotype of multidrug-resistant human glioblastoma multiforme cells. J Natl Cancer Inst 83: 1307-1315, 1991
23. Yung WK, Steck PA, Kelleher PJ, Moser RP, Rosenblum MG: Growth inhibitory effect of recombinant alpha and be-ta interferon on human glioma cells. J Neurooncol 5: 323-330, 1987
24. Baron S, Tyring SK, Fleischmann WR Jr., Coppenhaver DH, Niesel DW, Klimpel GR, Stanton GJ, Hughes TK: The interferons: mechanisms of action and clinical applications. JAMA 266: 1375-1383, 1991
25. Martinez R, Vaquero J, Ramiro J, Garcia Salazar F, De Oya S: Intratumoural and intraventricular human lymphoblastoid alpha interferon (HLBI) for treatment of glioblastoma multiforme. Acta Neurochir 100: 46-49, 1989
26. Jereb B, Petric J, Lamovec J, Skrbec M, Soss E: Intratumor application of human leukocyte interferon-alpha in patients with malignant brain tumors. Am J Clin Oncol 12: 1-7, 1989
27. Gehan EA: The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346-353, 1961
28. Smith DC, Trump DL: A phase I trial of high-dose oral tamoxifen and CHOPE. Cancer Chemother Pharmacol 36: 65-68, 1995
29. Stuart NSA, Philip P, Harris AL, Tonkin K, Houlbrook S, Kirk J, Lien EA, Carmichael J: High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. Br J Cancer 66: 833-839, 1992
30. Millward MJ, Cantwell BMJ, Lien EA, Carmichael J, Harris AL: Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer 28A: 805-810, 1992
31. Millward MJ, Lien EA, Robinson A, Cantwell BMJ: High-dose (480 mg/day) tamoxifen with etoposide: a study of a potential multi-drug resistance modulator. Oncology 51: 79-83, 1994
32. Berman E, McBride M, Lin S, Menendez-Botet C, Tong W: Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. Leukemia 9: 1631-1637, 1995
33. Papac RJ, Keohane MF: Hormonal therapy for metastatic renal cell carcinoma: combined androgen and provera followed by high dose tamoxifen. Eur J Cancer 29A: 997-999, 1993
34. Stahl M, Wilke H, Schmoll H-J, Schöber C, Diedrich H, Casper J, Freund M, Poliwoda H: A phase II study of high dose tamoxifen in progressive, metastatic renal cell carcinoma. Ann Oncol 3: 167-168, 1992
35. Stahl M, Schmoll E, Becker H, Schlichter A, Hoffmann L, Wagner H, Possinger K, Müller W, Köllermann M, Weidenhammer W, Schmoll H-J: Lonidamine versus high-dose tamoxifen in progressive, advanced renal cell carcinoma: results of an ongoing randomized phase II study. Semin Oncol 18 Suppl 4: 33-37, 1991
36. Delattre J-Y, Vega FB, Chen Q: Neurological complications of immunotherapy. In: Wiley RG (ed) Neurological Complications of Cancer. Marcel Dekker, New York 1995, pp 267-293
37. Kirkwood JM, Stawderman MH, Ernstoff MS, Smith MS, Borden EC, Blum RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14: 7-17, 1996
38. Kirkwood JM, Ernstoff MS: Interferons in the treatment of human cancer. J Clin Oncol 2: 336-352, 1984
39. Rohatiner AZS, Prior P, Burton A, Balkwill F, Lister TA: Central nervous system toxicity of interferon. Prog Exp Tumor Res 29: 197-202, 1985
40. Macheledt JE, Buzdar AU, Hortobagyi GN, Frye DK, Gutterman JU, Holmes FA: Phase II evaluation of interferon added to tamoxifen in the treatment of metastatic breast cancer. Breast Cancer Res Treat 18: 165-170, 1991
41. Porzsolt F, Otto AM, Trauschel B, Buck C, Wawer AW, Schönenberger H: Rationale for combining tamoxifen and interferon in the treatment of advanced breast cancer. J Cancer Res Clin Oncol 115: 465-469, 1989
42. Klein M, Krieger O, Ruckser R, Rosen A, Waldner R, Preis P, Beck A: Treatment of lymphangioleiomyomatosis by ovariectomy, interferon alpha 2b and tamoxifen - a case report. Arch Gynecol Obstet 252: 99-102, 1992
43. Prados MD, Schold SC, Spence AM, Berger MS, McAllister LD, Mehta MP, Gilbert MR, Fulton D, Chang SM: A phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 14: 2316-2321, 1996
44. Lesser GJ, Grossman SA, Eller S, Rowinsky EK: 3H-paclitaxel tissue concentrations within intracranial malignant gliomas and normal rat brains after intravenous administration. Proc Am Soc Clin Oncol 14: 149, 1995 (abstract)
45. Gattis W, May DB: Possible interaction involving phenytoin, dexamethasone, and antineoplastic agents: a case report and review. Ann Pharmacother 30: 520-526, 1996
46. Grossman SA, Sheidler VR, Gilbert MR : Decreased phenytoin levels in patients receiving chemotherapy. Am J Med 87: 505-510, 1989
47. Rabinowicz AL, Hinton DR, Dyck P, Couldwell WT: High-dose tamoxifen in treatment of brain tumors: interaction with antiepileptic drugs. Epilepsia 36: 513-515, 1995
48. Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C: MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36: 1-6, 1995
49. Schinkel AH, Wagenaar E, Mol CAAM, van Deemter L: P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 97: 2517-2524, 1996